Show simple item record

dc.contributor.authorPowles, Ten_US
dc.contributor.authorde Liano, AGen_US
dc.contributor.authorAckerman, Cen_US
dc.date.accessioned2020-09-08T14:16:48Z
dc.date.available2017-05-15en_US
dc.date.issued2017en_US
dc.identifier.issn0302-2838en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/66867
dc.format.extentE137 - E138en_US
dc.relation.ispartofEUROPEAN UROLOGYen_US
dc.titleReply to Pontus Eriksson, Gottfrid Sjodahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed <i>Protein Expression to Predict Outcome to Targeted Therapy in Bladder Cancer: Too Little, Too Late?</i>en_US
dc.typeArticle
dc.identifier.doi10.1016/j.eururo.2017.05.025en_US
pubs.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000412685300010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.issue5en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume72en_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record